CIBC Bancorp USA Inc. Takes $8.96 Million Position in Zoetis Inc. $ZTS

CIBC Bancorp USA Inc. bought a new position in shares of Zoetis Inc. (NYSE:ZTS) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 61,216 shares of the company’s stock, valued at approximately $8,957,000.

Several other institutional investors also recently bought and sold shares of ZTS. Alpine Global Management LLC purchased a new position in Zoetis in the third quarter valued at $473,000. Maple Capital Management Inc. lifted its holdings in Zoetis by 1.3% in the 3rd quarter. Maple Capital Management Inc. now owns 88,717 shares of the company’s stock valued at $12,981,000 after purchasing an additional 1,165 shares in the last quarter. Old North State Trust LLC lifted its stake in shares of Zoetis by 35.7% in the third quarter. Old North State Trust LLC now owns 2,867 shares of the company’s stock worth $419,000 after buying an additional 755 shares in the last quarter. Caerus Investment Advisors LLC purchased a new position in Zoetis in the 3rd quarter worth approximately $399,000. Finally, Danske Bank A S acquired a new position in Zoetis during the third quarter worth $58,068,000. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Stock Down 0.5%

ZTS stock opened at $115.43 on Friday. Zoetis Inc. has a 12 month low of $114.36 and a 12 month high of $172.23. The firm has a 50 day simple moving average of $124.35 and a 200 day simple moving average of $130.60. The firm has a market cap of $48.73 billion, a PE ratio of 19.17, a P/E/G ratio of 1.77 and a beta of 0.95. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The business had revenue of $2.39 billion for the quarter, compared to the consensus estimate of $2.36 billion. During the same period last year, the firm posted $1.40 earnings per share. The firm’s quarterly revenue was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Equities research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be issued a dividend of $0.53 per share. The ex-dividend date is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.8%. Zoetis’s dividend payout ratio (DPR) is currently 35.22%.

Analyst Ratings Changes

A number of research analysts have commented on the stock. Piper Sandler reaffirmed a “neutral” rating and issued a $135.00 target price (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. HSBC set a $140.00 price target on Zoetis in a research report on Wednesday, December 10th. Weiss Ratings upgraded shares of Zoetis from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, March 12th. UBS Group set a $136.00 target price on Zoetis in a research note on Thursday, January 29th. Finally, Morgan Stanley set a $160.00 target price on shares of Zoetis in a report on Thursday, December 18th. Six research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $152.91.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.